News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Oxygen Therapy Files S-1 Registration Statement



11/4/2016 11:24:51 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs

NEW YORK, NY--(Marketwired - November 02, 2016) - Oxygen Therapy, Inc. (the "Company"), the developer of innovative oxygen therapies for treating and protecting the brain during and after stroke, announced today that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission (the "SEC").

The registration statement has not yet become effective. The securities described in the registration statement may not be sold by the Company nor may offers to buy or to be accepted by the Company prior to the time the registration statement becomes effective.

Once the registration statement is declared effective, the subscription period is expected to stay open for approximately 90 days following the record date.

The Company intends to use the proceeds of this offering for general corporate purposes, which may include funding for product development, design of clinical trials, marketing, and general working capital purposes.

This press release shall not and does not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale, would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

The offering of the securities described in the registration statement is self-directed.

When available, copies of the prospectus relating to the offering may be obtained from the Company for the offering.

About Oxygen Therapy, Inc.
Oxygen Therapy Inc. is a biopharmaceutical company that develops anti-necrosis drugs that treat a variety of medical conditions resulting from ischemia. The Company focuses on the development and commercialization of first-in-class treatments to prevent catastrophic brain damage resulting from hypoxic conditions following brain stroke also known as Cardiac Cerebrovascular Accidents (CVA). The Company's lead product candidate, OTI-629, is an anti-necrosis drug that carries oxygen to brain tissues when the flow of blood is blocked. For more information, visit www.otipharma.com

Forward Looking Statements
Statements in this news release which are not purely historical, including statements regarding Oxygen Therapy, Inc.'s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the Company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the company's cash flow, market acceptance risks, and technical development risks. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Oxygen Therapy, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Related Links http://www.otipharma.com


Yuval Kwintner
President
202 Lenox Avenue
New York, NY 10026
Yuval.kwintner@otipharma.com
Tel: (646) 454-1384


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES